The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a “gpA33 x CD3 bi-specific monovalent diabody”). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a “gpA33 x CD3 bi-specific monovalent Fc diabody”). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.本發明涉及雙特異性單價雙抗體,其包括兩條多肽鏈並且其至少具有對CD3的抗原決定部位特異的一個結合位點和對gpA33的抗原決定部位特異的一個結合位點(即,“gpA33 x CD3雙特異性單價雙抗體”)。本發明也涉及雙特異性單價雙抗體,其包括免疫球蛋白Fc結構域(“雙特異性單價Fc雙抗體”)和由三條多肽鏈組成並且至少具有對gpA33的抗原決定部位特異的一個結合位點和對CD3抗原決定部位特異的一個結合位點(即,“gpA33 x CD3雙特異性單價Fc雙抗體”)。於此,雙特異性單價雙抗體和雙特異性單價Fc雙抗體能夠同時結合gpA33和CD3。本發明涉及包含這類雙特異性單價雙抗體或這類雙特異性單價Fc雙抗體的藥學組合物。本發明另外涉及使用這類雙抗體治療癌症和其他疾病和病況的方法。VL‧‧‧結構域VH‧‧‧結構域
